Everforth Inc quarterly report, Q3 FY2000

Business Context and Reporting Period

Company: On Assignment, Inc. (Note: Input metadata referenced "Everforth Inc," but the filing text identifies the registrant as On Assignment, Inc.)
Filing Type: Form 10-Q
Reporting Period: Quarter and nine months ended September 30, 2000
Business Overview: The Company provides temporary and permanent placement services through two reportable segments: Lab Support (laboratory, scientific, and environmental professionals) and Healthcare Staffing (medical billing, collection, and clinical staffing).

Key Financial Metrics

Metric Three Months Ended
Sep 30, 2000
Nine Months Ended
Sep 30, 2000
Revenues $51,109,000 $143,272,000
Gross Profit $16,781,000 $46,882,000
Gross Margin 32.8% 32.7%
Operating Income $7,434,000 $20,309,000
Net Income $5,095,000 $13,825,000
Diluted EPS $0.22 $0.60
Cash from Operations (9mo) $16,586,000
Cash & Equivalents (Sep 30, 2000) $44,792,000
Total Current Liabilities $10,705,000

Material Changes vs. Prior Period

  • Revenue Growth: Revenues increased 21.0% for the quarter and 23.2% for the nine-month period compared to the prior year.
    • Lab Support: Revenue grew 17.3% (quarter) and 17.3% (nine months), driven by a 12.1% increase in temporary employees and a 171.6% surge in conversion fees. Growth was partially offset by a 22.5% decline in the EnviroStaff division due to a strategic shift away from remediation clients.
    • Healthcare Staffing: Revenue grew 31.6% (quarter) and 41.6% (nine months), driven by a 31.4% increase in temporary employees and a 130.0% increase in conversion fees.
  • Profitability: Net income increased 34.7% for the quarter and 34.2% for the nine-month period. Operating margins improved slightly due to the leverage of centralized support systems over a larger revenue base.
  • Cost Structure: Cost of services increased 20.7% (quarter) and 22.7% (nine months), tracking revenue growth. Selling, general, and administrative (SG&A) expenses increased 14.3% (quarter) and 17.7% (nine months) but decreased as a percentage of revenue (from 19.4% to 18.3% in the quarter).
  • Liquidity: Cash and cash equivalents increased from $24.1 million to $44.8 million. Net cash provided by operating activities more than doubled to $16.6 million for the nine-month period.

Guidance, Outlook, and Risks

  • Outlook: Management believes current cash balances, funds from operations, and borrowing ability are sufficient to meet requirements for the next twelve months. No specific numerical guidance for future periods was provided in this filing.
  • Segment Restructuring: Effective Q1 2000, the Clinical Lab Staff division was reclassified from Lab Support to Healthcare Staffing. Prior period data has been restated.
  • Acquisitions: The Company completed the final contingent payment ($360,000) for the 1998 acquisition of LabStaffers, Inc. in July 2000.
  • Risks: Key risks include the ability to attract and retain qualified Account Managers and temporary employees, management of growth in international markets, and integration of acquired operations. The Company is exposed to interest rate and foreign currency risks, though management deems the impact of a 10% currency fluctuation immaterial.

Investor Verification Checklist

  • EnviroStaff Decline: Verify the strategic rationale and timeline for the continued revenue decline in the EnviroStaff division (down 22.5% QoQ).
  • Conversion Fee Volatility: Assess the sustainability of the significant increase in conversion fee revenue (up 171.6% in the quarter), which contributed heavily to segment growth.
  • Working Capital Trends: Monitor the increase in accounts receivable ($5.2 million increase in the nine-month period) relative to revenue growth to ensure collection efficiency.
  • Stock Repurchases: Note that the Company halted stock repurchases in the current period (0 repurchases vs. $4.8 million in the prior year) while generating significant cash from option exercises ($7.4 million).
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.